Abel Hall LLC Purchases 14,395 Shares of Pfizer Inc. $PFE

Abel Hall LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 125.1% during the second quarter, Holdings Channel.com reports. The firm owned 25,900 shares of the biopharmaceutical company’s stock after buying an additional 14,395 shares during the quarter. Abel Hall LLC’s holdings in Pfizer were worth $628,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Bessemer Group Inc. increased its stake in shares of Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock worth $3,358,000 after purchasing an additional 13,228 shares during the period. Capital Advisors Inc. OK grew its position in Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after buying an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp acquired a new stake in Pfizer during the first quarter worth approximately $8,283,000. Westbourne Investments Inc. acquired a new stake in Pfizer during the first quarter worth approximately $2,411,000. Finally, Bourne Lent Asset Management Inc. grew its position in Pfizer by 90.8% during the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after buying an additional 18,200 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.6%

Shares of PFE stock opened at $26.27 on Wednesday. The stock’s fifty day moving average price is $24.76 and its two-hundred day moving average price is $24.14. The company has a market cap of $149.36 billion, a PE ratio of 13.97, a P/E/G ratio of 0.86 and a beta of 0.55. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

PFE has been the topic of a number of analyst reports. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Bank of America increased their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.